Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Interest Expenses (2016 - 2025)

ImmunityBio (IBRX) has disclosed Interest Expenses for 9 consecutive years, with $14.8 million as the latest value for Q4 2025.

  • Quarterly Interest Expenses fell 42.96% to $14.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.9 million through Dec 2025, down 46.87% year-over-year, with the annual reading at $60.9 million for FY2025, 46.87% down from the prior year.
  • Interest Expenses for Q4 2025 was $14.8 million at ImmunityBio, down from $15.3 million in the prior quarter.
  • The five-year high for Interest Expenses was $35.0 million in Q3 2023, with the low at -$18.7 million in Q4 2022.
  • Average Interest Expenses over 5 years is $15.2 million, with a median of $15.3 million recorded in 2025.
  • The sharpest move saw Interest Expenses tumbled 515.43% in 2022, then skyrocketed 6405.25% in 2024.
  • Over 5 years, Interest Expenses stood at $4.5 million in 2021, then crashed by 515.43% to -$18.7 million in 2022, then skyrocketed by 102.14% to $400000.0 in 2023, then surged by 6405.25% to $26.0 million in 2024, then crashed by 42.96% to $14.8 million in 2025.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $14.8 million, $15.3 million, and $15.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.